Reported 1 day ago
Novo Nordisk's stock plummeted over 20% in pre-market trading due to disappointing results from its clinical trial for the weight-loss injection CagriSema, which showed lower weight loss than anticipated. This decline contrasts sharply with competitor Eli Lilly, highlighting the competitive landscape in the weight-loss drug market.
Source: YAHOO